ALK-IN-29

• Description :

  ALK-IN-29 (compound 4c) has a certain inhibitory effect on tyrosine protein kinases ALK, CDK2/CyclinE1 and FAK, among which the strongest inhibitory effect on ALK kinase is 40.63% at a concentration of 10 μM. ALK-IN-29 can be used for anti-cancer research[1].

• UNSPSC :

  12352101

• Target :

  Anaplastic lymphoma kinase (ALK) ; CDK; FAK

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage; Protein Tyrosine Kinase/RTK

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/alk-in-29.html

• Smiles :

  O[C@H](C1)CC[C@@]2(C)C1=CC[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC(C4=N5)=C(C6=CC=C(F)C=C6)N7C5=CC=N7

• Molecular Formula :

  C29H32FN3O

• Molecular Weight :

  457.58

• References & Citations :

  [1]Liu F, et al. Heterocycle-functional steroidal derivatives: Design, synthesis, bioevaluation and SARs of steroidal pyrazolo[1,5-a]pyrimidines as potential ALK inhibitors. Bioorg Chem. 2024 Sep 27;153:107847.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  CDK2